Programmed cell removal: a new obstacle in the road to developing cancer.
about
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implicationsBeneficial autoimmunity at body surfaces - immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancerTo be or not to be? How selective autophagy and cell death govern cell fateThe Dynamics of Apoptotic Cell ClearanceStem cells are units of natural selection for tissue formation, for germline development, and in cancer developmentMetabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity.Breast cancer stem cells: Multiple capacities in tumor metastasis.Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patientsEngagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.The Role of Efferocytosis in Atherosclerosis.Pathway-gene identification for pancreatic cancer survival via doubly regularized Cox regressionMacrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk.CD47-independent effects mediated by the TSP-derived 4N1K peptide.Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.FAM96A is a novel pro-apoptotic tumor suppressor in gastrointestinal stromal tumors.Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals.CSB ablation induced apoptosis is mediated by increased endoplasmic reticulum stress responseHIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells.Immunosurveillance and immunotherapy of tumors by innate immune cells.Activation of apoptosis in hepatocellular carcinoma by the Chinese traditional medicine Hu Qisan.Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors.Durable antitumor responses to CD47 blockade require adaptive immune stimulation.Helicobacter pylori infection inhibits phagocyte clearance of apoptotic gastric epithelial cells.CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.In-silico insights on the prognostic potential of immune cell infiltration patterns in the breast lobular epithelium.A rapid, automated surface protein profiling of single circulating exosomes in human blood.Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Dendritic cell-based immunotherapy for myeloid leukemias.Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Carboplatin Effects Against Ovarian Cancer.Is CD47 an innate immune checkpoint for tumor evasion?The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment.A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.MUC1: a novel metabolic master regulator.Evolution of normal and neoplastic tissue stem cells: progress after Robert Hooke.The mitochondrial apoptotic pathway is induced by Cu(II) antineoplastic compounds (Casiopeínas®) in SK-N-SH neuroblastoma cells after short exposure times.Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 signaling.
P2860
Q24568313-E2C03435-D2BC-4B5C-A3CE-2456DA3DA5ECQ24605052-22B1BE8A-978B-427E-B72B-7266D892470DQ26865509-50E2B978-8148-4196-93F4-E7FD4710F99EQ28385846-69EE6A58-29BC-4617-A19A-7D86DE3E30EEQ30276273-436A60C2-26F9-4AF4-BD95-3D264AA7E81CQ30659198-9029E02E-E586-4F5B-A413-8E89D64264B4Q33993449-54F4DC9C-D148-451D-94F3-CC2CD7CC24BFQ34257303-C7358EE2-1EDD-463C-B399-BDD9963A4DD2Q34483478-08F9D34C-2E85-44E6-9F89-A5B5B56A88A8Q34548156-FC9D981E-A1DB-4F9C-B94C-25C2B97130CFQ34680660-549DBBDE-82C4-49FB-AC02-12715D524A9FQ35102086-6603143F-DDD5-4FB4-9930-4B489241DDFDQ35129097-5B300E1E-1B9B-4CDE-84AF-2D7DCFF29C28Q35171992-9A2D806A-717B-4B15-8D56-D35AFD402032Q35781873-56AAE754-7F13-40AC-AA68-0FDBF83D56C7Q35836497-F1322B12-9324-4881-B61B-70F901079AAAQ35993525-84CA4089-1B28-49F4-B53D-7E168272DA21Q36137576-D7D50974-CB92-4D3E-8529-FC526F905C66Q36208486-81F0EC6B-21E2-4E1E-B12C-3A0AF3758B19Q36295557-06E58456-5739-464E-8AFD-E31C8AEBFA9AQ36300305-1A416A63-4CAC-47C5-84EE-A48FF5C490EAQ36471212-A0611FEA-53D5-4088-BAA6-8257695BCC47Q36603935-5265C84E-E6D5-451D-943B-E2DBDF76102FQ36637556-201B9455-BDF2-45C6-BD67-1D576FD07439Q36831577-3EAB9E05-7CE9-4216-A4B7-883A4602D6E3Q36904867-654B736A-C0D6-4E93-AB28-4AE7A5A07405Q37051157-1C665B10-0E39-403F-A2DF-EE68007FD3EDQ37165792-7687F72C-0B62-4584-9BC8-B1BEB17B624BQ37277957-93691141-76FD-4DC9-B77A-26A3AEDC13ADQ37397211-185338A6-962C-4F50-BDAC-34C1D791B5E6Q37417271-3AFEEBC5-453C-484B-8760-C168C61BF282Q37420778-6C277200-2550-4F9E-9459-69304094CA39Q37502083-558CF334-5FD1-4929-AAE5-A8B156240475Q37579038-37B65D31-1E05-472F-8341-AC1308D2C79AQ37727786-AF5CD548-4B3A-4F5E-9ED3-AB4204AA533AQ37740931-626F7D20-D43B-49EF-BD69-57BF926C8655Q38177983-F0AB18D8-9967-49D7-8C21-76EE9F1C86E5Q38594905-5AFB2C86-43E6-4C9B-B1CB-F37BDF86CAAEQ38725601-F7D15330-DAE6-46A0-B0D0-A0A417EAA368Q38830839-D289F39A-DCBE-4F76-A3ED-D44638865CE9
P2860
Programmed cell removal: a new obstacle in the road to developing cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Programmed cell removal: a new obstacle in the road to developing cancer.
@en
Programmed cell removal: a new obstacle in the road to developing cancer.
@nl
type
label
Programmed cell removal: a new obstacle in the road to developing cancer.
@en
Programmed cell removal: a new obstacle in the road to developing cancer.
@nl
prefLabel
Programmed cell removal: a new obstacle in the road to developing cancer.
@en
Programmed cell removal: a new obstacle in the road to developing cancer.
@nl
P2093
P2860
P356
P1476
Programmed cell removal: a new obstacle in the road to developing cancer.
@en
P2093
Irving L Weissman
Mark P Chao
Ravindra Majeti
P2860
P2888
P356
10.1038/NRC3171
P407
P577
2011-12-08T00:00:00Z